Trials / Recruiting
RecruitingNCT07219511
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Vasa Therapeutics · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VS-041 | VS-041 high dose, VS-041 low dose or Placebo tablet BID |
| OTHER | Placebo | Placebo to match VS-041 |
Timeline
- Start date
- 2025-11-04
- Primary completion
- 2026-06-01
- Completion
- 2026-07-01
- First posted
- 2025-10-22
- Last updated
- 2026-04-09
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07219511. Inclusion in this directory is not an endorsement.